𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Observations on switching patients with schizophrenia to risperidone treatment

✍ Scribed by G. K. Kirov; R. M. Murray; R. V. Seth; S. Feeney; the Risperidone Switching Study Group

Book ID
114785874
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
499 KB
Volume
95
Category
Article
ISSN
0001-690X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term treatment with long-acting ris
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia
✍ Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give

Switching stable patients with schizophr
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety
✍ Chris Hawley; Martin Turner; Muhammud A Latif; Vivienne Curtis; Packeruther T Sa 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 2 views

## Abstract ## Objective An international, non‐randomised study evaluated efficacy and safety of risperidone long‐acting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here. ## Method

Effects of switching to long-acting inje
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
✍ Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Seung-Hyun Lee; Yo-Han Lee; Su-Jin Yang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral